Diabetic ketoacidosis (DKA) is a potentially life-threatening complication of type 1 diabetes mellitus. It is caused by the formation of ketone bodies from hepatic fatty acid oxidation due to insulin deficiency. DKA can be managed by fluid and potassium replacement and intravenous insulin infusion. However, monitoring capillary ketones, capillary glucose, serum electrolytes, and venous pH is essential for managing DKA.
Despite the availability of advanced type 2 diabetes mellitus (T2DM) management guidelines and therapies, poor glycemic control in T2DM patients is a major problem worldwide. Patient- and healthcare-provider-identified barriers to insulin therapy lead to a delay in initiating and intensifying insulin therapy and, thus, poor glycemic control among the patients. To learn more about DKA and barriers to insulin therapy, join the reputed endocrinologists and diabetologists…
